Yasheng Group Resumes Plan to Pay Preferred Dividend to Common Shareholders; Raise Capital for our Subsidiary, Jove Pharmaceutics In Order to Bring Next Generation Cancer Curing Cell Therapeutics to M
The original release is unavailable here.
Earlier from Yasheng
- Yasheng Group Teams Up with Jove Pharmaceutics In Order to Bring Next Generation Cancer Curing Cell Therapeutics to Market
- Yasheng Group Reports Financial Results for the Second Quarter, 2022
- Yasheng Group Reports Full-Year 2021 Financial Results: Sets New Spin-Off Date; Updates on Solar and Mining Projects